Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mersana Therapeutics excels in 2022, poised for oncology innovation

Mersana Therapeutics demonstrated strong performance, financial stability, and clinical progress in 2022, positioning themselves as a key player in oncology drug development.
While facing challenges in regulatory considerations and competitive dynamics, the company's strategic collaborations and pipeline advancements offer promising opportunities for future growth.
Investors should monitor Mersana's upcoming milestones, including data reporting and trial progress, as indicators of their potential for continued success and innovation.

Mersana Therapeutics progresses in Q1 with strong financials and clinical trials

Mersana Therapeutics is on track for a pivotal year with strong financials, progress in clinical trials, and plans for potential BLA submission. Challenges include diagnostic testing bottlenecks and patient pre-treatment impact on response rates. Opportunities exist in data presentations, partnerships, and subgroup analysis for improved outcomes.

Mersana Therapeutics reports improved Q3 performance and strategic partnerships

Mersana Therapeutics demonstrated improved financial performance, strong partnerships, and a focus on innovative ADC candidates. While facing challenges with clinical setbacks, the company's strategic restructuring and promising pipeline indicate opportunities for growth and success in the ADC market.

Mersana Therapeutics shows financial improvement and pipeline promise in Q1

Mersana Therapeutics demonstrated improved financial performance in Q1 2024 with reduced expenses and a lower net loss compared to the previous year.
Strengths in ADC platform advancements and promising lead candidates position Mersana well for future growth and innovation.
Challenges in clarifying key strategies and managing expenses underscore areas for improvement, while opportunities in expansion and partnerships offer avenues for advancement.

Mersana Therapeutics reports strong Q2 progress amidst financial challenges

Mersana Therapeutics demonstrated strong progress in Q2 2024 with promising clinical data for XMT-1660 and XMT-2056 ADC candidates, despite reporting a net loss.
The company's focus on optimizing dosing schedules, exploring biomarkers, and addressing resistance mechanisms underscores a commitment to advancing its pipeline.
Analysts' interest in patient responses, dosing schedules, and expansion plans highlights the market's anticipation of Mersana's future growth and innovation in the ADC space.

Mersana Therapeutics progresses ADC trials, strengthens finances, and faces resistance

Mersana Therapeutics demonstrated strong performance in advancing ADC candidates and managing finances effectively in Q3 2024.
While facing challenges such as resistance to existing ADCs, the company is well-positioned to capitalize on opportunities in innovative therapies.
Strategic planning for clinical trial expansions and business development will be crucial for Mersana's continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Aileron Therapeutics

CymaBay Therapeutics

Energy Focus

MicroVision

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

5 Top Stocks Up 100%+ in May With More Room to Run

Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Mersana Therapeutics (MRSN) in Focus: Stock Moves 8.3% Higher

CAMBRIDGE, Mass., May  28, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $19.00 per share. Gross proceeds to Mersana from the offering are expected to be $152.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Mersana. In addition, Mersana has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock, at the public offering price less underwriting discounts and commissions. All shares are being sold by Mersana. The offering is expected to close on June 2, 2020, subject to the satisfaction of customary closing conditions.

Mersana Therapeutics Announces Pricing of Public Offering of Common Stock

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Mersana Stock Spikes on Interim Data on Cancer Candidate

Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Mersana Therapeutics (MRSN) Stock Might be a Great Pick?

CAMBRIDGE, Mass., May  28, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of 5 million shares of its common stock. All shares being offered are to be sold by Mersana. As part of the offering, Mersana intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering, at the public offering price less underwriting discounts and commissions.

Mersana Therapeutics Announces Proposed Public Offering of Common Stock

Shares of biotech firm Mersana Therapeutics (MRSN) soared on Wednesday, closing up 69% to $18.19 per share. What was the cause

Why Mersana Therapeutics (MRSN) Spiked 69% Today

Mersana Therapeutics (NASDAQ: MRSN) shares are trading higher on Wednesday. The company reported interim safety, tolerability and efficacy data from the ongoing expansion portion of its Phase 1 study evaluating XMT-1536.

Why Mersana Therapeutics's Stock Is Trading Higher Today

Investors are excited about the biotech's encouraging results from an early-stage clinical trial.

Why Mersana Therapeutics Stock Is Skyrocketing Today

Mersana Therapeutics Inc. (NASDAQ: MRSN) shares jumped on Wednesday after the company reported interim results from its early-stage cancer study.

Why Mersana’s Cancer Study Is Huge

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

Beyond Meat

Cardlytics

Chegg

Okta

Pinterest

Plug Power

Virgin Galactic

Trade Desk

These 10 up-and-coming stocks are among some of the best hyper-growth stocks investors should buy for the next decade of gains.

10 Up-And-Coming Stocks to Buy for the Next 10 Years

CAMBRIDGE, Mass., May  14, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in a Phase 1 dose escalation study evaluating XMT-1592, its Dolasynthen ADC targeting NaPi2b. XMT-1592 is the Company’s first clinical candidate created using its new customizable and homogenous Dolasynthen ADC platform.

Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study

CAMBRIDGE, Mass., May  13, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present interim data from the ongoing Phase 1 expansion evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma. The data will be presented in a poster session featuring study investigator, Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held from May 29 – May 31, 2020.

Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q1 2020 Results - Earnings Call Transcript

MGM Resorts

Stitch Fix

Simply Good Foods

Williams-Sonoma

Insider buying hit record-highs in March. Of all the stocks that saw huge insider buying recently, these are the top stocks to buy.

5 Stocks to Buy With Heavy Insider Buying

CAMBRIDGE, Mass., April  15, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Martin H. Huber, M.D., to its Board of Directors, effective immediately.

Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D.

The company raised more money to keep developing potential new cancer therapies.

Here's Why Mersana Therapeutics Stock Is Soaring Today

CAMBRIDGE, Mass., April  07, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it has raised gross proceeds of approximately $65 million through its At-the-Market (ATM) facility with participation based on interest received from Avoro Capital Advisors LLC, Bain Capital Life Sciences, Consonance Capital Investors and David Mott, Mersana’s Chairman of the Board. The Company sold approximately 8.9 million shares of the Company’s common stock at a purchase price of $5.59 and 2.0 million shares at the closing price of $7.74, in each case the market price at the time of sale.  Cowen is acting as the sales agent for the ATM facility.

Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility

AvroBio Inc

Fate Therapeutics

Kiniksa Pharmaceuticals Ltd

Novocure

Orchard Therapeutics plc - ADR

Synlogic

Tcr2 Therapeutics

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

What Wedbush Is Watching in Biotechs Amid Coronavirus Crisis

Clinical-trial results from the company's first proof-of-concept study were disappointing.

Here's Why Mersana Therapeutics Is Sinking Today

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

Will Mersana Therapeutics Continue to Surge Higher?

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript

Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session

XMT-1536 On Track to Demonstrate Proof of Concept in Both Ovarian and Non-Small Cell Lung Cancer with Multiple Data Readouts Expected Throughout 2020

News for Mersana Therapeutics Stock (MRSN)